85 related articles for article (PubMed ID: 16387700)
1. ProtEx: a novel technology to display exogenous proteins on the cell surface for immunomodulation.
Singh NP; Yolcu ES; Askenasy N; Shirwan H
Ann N Y Acad Sci; 2005 Nov; 1056():344-58. PubMed ID: 16387700
[TBL] [Abstract][Full Text] [Related]
2. A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity.
Singh NP; Yolcu ES; Taylor DD; Gercel-Taylor C; Metzinger DS; Dreisbach SK; Shirwan H
Cancer Res; 2003 Jul; 63(14):4067-73. PubMed ID: 12874008
[TBL] [Abstract][Full Text] [Related]
3. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection.
Yolcu ES; Askenasy N; Singh NP; Cherradi SE; Shirwan H
Immunity; 2002 Dec; 17(6):795-808. PubMed ID: 12479825
[TBL] [Abstract][Full Text] [Related]
4. Display of Fas ligand protein on cardiac vasculature as a novel means of regulating allograft rejection.
Askenasy N; Yolcu ES; Wang Z; Shirwan H
Circulation; 2003 Mar; 107(11):1525-31. PubMed ID: 12654611
[TBL] [Abstract][Full Text] [Related]
5. Mouse T cells engineered to display on their surface a novel form of FasL protein undergo apoptosis when stimulated with alloantigens: implications for graft-versus-host disease.
Yolcu ES; Singh NP
Transplant Proc; 2013 Jun; 45(5):1850-2. PubMed ID: 23769056
[TBL] [Abstract][Full Text] [Related]
6. GM-CSF-surface-modified B16.F10 melanoma cell vaccine.
Gao J; Huang S; Li M; Luo R; Wang X; Takashima A
Vaccine; 2006 Jun; 24(25):5265-8. PubMed ID: 16713660
[TBL] [Abstract][Full Text] [Related]
7. Regulation of the complement-mediated elimination of red blood cells modified with biotin and streptavidin.
Muzykantov VR; Murciano JC; Taylor RP; Atochina EN; Herraez A
Anal Biochem; 1996 Oct; 241(1):109-19. PubMed ID: 8921172
[TBL] [Abstract][Full Text] [Related]
8. In vitro immune modulation by antibodies coupled to tumour cells.
Darling D; Galea-Lauri J; Gäken J; Towner P; Kuiper M; Hollingsworth S; Hirst W; Barnard A; Buggins A; Mufti G; Farzaneh F
Gene Ther; 1997 Dec; 4(12):1350-60. PubMed ID: 9472559
[TBL] [Abstract][Full Text] [Related]
9. Overexpressed exogenous IL-4 And IL-10 paradoxically regulate allogenic T-cell and cardiac myocytes apoptosis through FAS/FASL pathway.
Furukawa H; Oshima K; Tung T; Cui G; Laks H; Sen L
Transplantation; 2008 Feb; 85(3):437-46. PubMed ID: 18301335
[TBL] [Abstract][Full Text] [Related]
10. Generation of a multimeric form of CD40L with potent immunostimulatory activity using streptavidin as a chaperon.
Kilinc MO; Mukundan L; Yolcu ES; Singh NP; Suttles J; Shirwan H
Exp Mol Pathol; 2006 Jun; 80(3):252-61. PubMed ID: 16487512
[TBL] [Abstract][Full Text] [Related]
11. Primary tumor cells resected from cancer patients and decorated with a novel form of CD80 protein serve as effective antigen-presenting cells for the induction of autologous T cell immune responses ex vivo.
Singh NP; Miller RW; Yolcu ES; Kilinc MO; Oechsli M; Huseby R; Taylor DD; Perry MT; Larocca RV; Shirwan H
Hum Gene Ther; 2006 Mar; 17(3):334-46. PubMed ID: 16544982
[TBL] [Abstract][Full Text] [Related]
12. Suppression of the cell-mediated immune response by a Fas-immunoglobulin fusion protein.
Shen Y; Young B; Lipman ML
Transplantation; 2006 Apr; 81(7):1041-8. PubMed ID: 16612282
[TBL] [Abstract][Full Text] [Related]
13. Biotinylation and characterization of Cryptococcus neoformans cell surface proteins.
Foster AJ; Bird RA; Smith SN
J Appl Microbiol; 2007 Aug; 103(2):390-9. PubMed ID: 17650199
[TBL] [Abstract][Full Text] [Related]
14. Biotechnological applications for surface-engineered bacteria.
Wernérus H; Ståhl S
Biotechnol Appl Biochem; 2004 Dec; 40(Pt 3):209-28. PubMed ID: 15035661
[TBL] [Abstract][Full Text] [Related]
15. Exploiting the tumor microenvironment in the development of targeted cancer gene therapy.
Dougherty GJ; Dougherty ST
Cancer Gene Ther; 2009 Mar; 16(3):279-90. PubMed ID: 18818709
[TBL] [Abstract][Full Text] [Related]
16. Tumor cells expressing a fusion protein of MULT1 and Fas are rejected in vivo by apoptosis and NK cell activation.
Kotturi HS; Li J; Branham-O'Connor M; Stickel SL; Yu X; Wagner TE; Wei Y
Gene Ther; 2008 Oct; 15(19):1302-10. PubMed ID: 18463688
[TBL] [Abstract][Full Text] [Related]
17. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
18. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
[TBL] [Abstract][Full Text] [Related]
19. [Construction of autocatalytic caspase-3 driven by amplified human telomerase reverse transcriptase promoter and its enhanced efficacy of inducing apoptosis in human ovarian carcinoma].
Song Y; Shen K; He CX
Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):617-22. PubMed ID: 17983518
[TBL] [Abstract][Full Text] [Related]
20. CTLA-4.FasL inhibits allogeneic responses in vivo.
Dranitzki-Elhalel M; Huang JH; Rachmilewitz J; Pappo O; Parnas M; Schmidt W; Tykocinski ML
Cell Immunol; 2006 Feb; 239(2):129-35. PubMed ID: 16828466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
